Journal
EUROPEAN JOURNAL OF CANCER
Volume 43, Issue 10, Pages 1622-1629Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.ejca.2007.03.018
Keywords
vascular targeting; CA4P KHT sarcoma; DCE-MRI; cytokines
Categories
Funding
- NCI NIH HHS [R01 CA084408-11, CA-84408, R01 CA084408, R01 CA089655] Funding Source: Medline
Ask authors/readers for more resources
The purpose of this study was to investigate two non-invasive methods for determining the treatment efficacy of the vascular disrupting agent (VDA) CA4P: gadolinium enhanced dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) for perfusion analysis and enzyme-linked immunosorbent assay (ELISA) of blood samples. Candidate proteins were identified by multi-analyte profile analysis of plasma from KHT sarcoma-bearing C3H/HeJ mice after CA4P administration. Candidate proteins were further analysed by ELISA of plasma from treated C3H/HeJ, BALBc and C57BL6 mice. Changes in selected proteins, tumour perfusion and tumour necrotic fraction after CA4P treatment were then compared in individual animals. The cytokines KC and MCP-1 were observed to increase after CA4P treatment in all tested models. No correlation was found between KC or MCP-1 levels and tumour necrosis. However, tumour perfusion correlated (r = 0.89, p < 0.00001) with CA4P treatment efficacy as measured by necrotic fraction, suggesting that DCE-MRI may have utility in a clinical setting. (C) 2007 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available